ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 185.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-06-01
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -1.67M shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 727.00K shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 1.12M shares, a 37.26% decline year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 185.00K shares, a 0.54% increase from fiscal 2024.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 184.00K shares, a 83.79% decline from fiscal 2023.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.14M shares, a 3.65% increase from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.09M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -1.67M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -938.00K shares derived: sum of 2 quarters · filed 2026-06-01 | -938.00K shares derived: sum of 3 quarters · filed 2026-06-01 | 185.00K shares 10-K · filed 2026-06-01 | |
| 2025-09-30 | 727.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | 727.00K shares derived: sum of 2 quarters · filed 2025-11-19 | 1.85M shares 10-Q · filed 2025-11-19 | 194.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.12M shares 10-Q · filed 2025-08-13 | -533.00K shares derived: sum of 3 quarters · filed 2026-06-01 | -533.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-03-31 | 1.12M shares 10-Q · filed 2025-05-20 | -533.00K shares derived: sum of 2 quarters · filed 2026-06-01 | -533.00K shares derived: sum of 3 quarters · filed 2026-06-01 | -483.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2024-12-31 | -1.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -1.66M shares derived: sum of 2 quarters · filed 2026-06-01 | -1.61M shares derived: sum of 3 quarters · filed 2026-06-01 | 184.00K shares 10-K · filed 2026-06-01 | 1.84M shares 10-K · filed 2025-04-01 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 50.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.84M shares 10-Q · filed 2024-11-13 | 1.85M shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2024-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.84M shares 10-Q · filed 2024-08-14 | 1.85M shares derived: sum of 3 quarters · filed 2025-04-01 | 1.85M shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2024-03-31 | 1.79M shares 10-Q · filed 2024-05-10 | 1.80M shares derived: sum of 2 quarters · filed 2025-04-01 | 1.80M shares derived: sum of 3 quarters · filed 2025-04-01 | 1.92M shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2023-12-31 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | 10.00K shares derived: sum of 2 quarters · filed 2025-04-01 | 130.00K shares derived: sum of 3 quarters · filed 2025-04-01 | 1.14M shares 10-K · filed 2025-04-01 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 120.00K shares derived: sum of 2 quarters · filed 2023-11-13 | 1.13M shares 10-Q · filed 2023-11-13 | 485.00K shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-06-30 | 120.00K shares 10-Q · filed 2023-08-11 | 1.13M shares 10-Q · filed 2023-08-11 | 485.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 1.02M shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-03-31 | 205.00K shares 10-Q · filed 2023-05-12 | 365.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 900.00K shares derived: sum of 3 quarters · filed 2024-03-29 | ||
| 2022-12-31 | 160.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 695.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 1.09M shares 10-K · filed 2024-03-29 | ||
| 2022-09-30 | 535.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 935.00K shares 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 400.00K shares 10-Q · filed 2022-08-12 | ||||
| 2018-12-31 | 2.49M shares 10-K · filed 2019-03-26 | ||||
| 2018-06-30 | 2.33K shares 10-Q · filed 2019-08-12 | ||||
| 2017-12-31 | 600.00K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-03-26 | 25.00K shares derived: sum of 2 quarters · filed 2019-03-26 | 625.00K shares 10-K · filed 2019-03-26 | ||
| 2017-09-30 | -575.00K shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20 | 25.00K shares 10-Q/A · filed 2018-08-20 | |||
| 2017-06-30 | 600.00K shares 10-Q/A · filed 2018-08-20 | ||||
| 2014-12-31 | 147.50K shares 10-K · filed 2017-02-24 | 148.00K shares 10-K · filed 2015-03-27 | |||
| 2013-12-31 | 420.50K shares 10-K · filed 2016-03-29 | ||||
| 2012-12-31 | 15.00K shares 10-K · filed 2015-03-27 | ||||
| 2011-12-31 | 220.00K shares 10-K · filed 2014-03-27 | ||||
| 2010-12-31 | 982.00K shares 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |